Immuron seeking FDA approval for travelers’ diarrhea drug candidate
Finfeed
Archived
Apr 11, 2019
Australian biopharmaceutical company, Immuron Limited (ASX: IMC |NASDAQ: IMRN), plans to pursue clinical development of IMM-124E, its bovine polyclonal antibody drug candidate to prevent travelers’ diarrhea, through a formal FDA registration pathway.